| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On July 27, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1996N-0417
|
| CGMP in Mfg. Packing or Holding Dietary Supplements
|
|
|
|
|
| 2006D-0480
|
| Guidance for Industry
on Complementary & Alternative Medicine Products & Their Regulation
by the Food and Drug Administration
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| 2007P-0296
|
| Request that the FDA requires labeling changes for Skelaxin (active ingredient metaxalone) as set forth in the proposed revised packaging insert
|
|
| |
|
| 1996N-0417
|
| CGMP in Mfg. Packing or Holding Dietary Supplements
|
|
|
|
|
| C 257
|
| Phillip Johnson
|
| Vol #:
|
| 43
|
|
|
|
|
| C 258
|
| Tanara Greywolf
|
| Vol #:
|
| 43
|
|
|
|
|
| C 259
|
| Brishen Thomas
|
| Vol #:
|
| 43
|
|
|
|
|
| 2006D-0480
|
| Guidance for Industry
on Complementary & Alternative Medicine Products & Their Regulation
by the Food and Drug Administration
|
|
|
|
|
| C 1366
|
| Theresa Arsby
|
| Vol #:
|
| 25
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| C 23
|
| Unknown
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0296
|
| Request that the FDA requires labeling changes for Skelaxin (active ingredient metaxalone) as set forth in the proposed revised packaging insert
|
|
|
|
|
| CP 1
|
| Zuckerman Spaeder LLP
|
| Vol #:
|
| 1
|
|
